Interim report of the UKCLL02 Trial: a phase II study of subcutaneous alemtuzumab plus fludarabine in patients with fludarabine refractory CLL (on behalf of the NCRI CLL Trials Sub-Group)

被引：0
|
作者：
Sayala, HA
Moreton, P
Jones, RA
Rawstron, AC
O'Connor, SJ
Evans, P
Carter, A
Dearden, C
Matutes, E
Pettitt, AR
Kennedy, DB
Hillmen, P
机构：
[1] Leeds Gen Infirm, HMDS, Leeds, W Yorkshire, England
[2] Royal Liverpool Univ Hosp, Dept Haematol, Liverpool, Merseyside, England
[3] Inst Canc Res, Haematooncol Dept, London SW3 6JB, England
[4] Leicester Royal Infirm, Dept Haematol, Leicester, Leics, England
来源：
BRITISH JOURNAL OF HAEMATOLOGY | 2006年 / 133卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：3 / 3
页数：1
相关论文
共 50 条
  • [41] Analysis of minimal residual disease (MRD) from the phase 2 multicenter study of subcutaneous (SC) alemtuzumab combined with fludarabine for treatment of relapsed/refractory B-cell chronic lymphocytic leukemia (CLL).
    Flowers, Christopher
    Rosenthal, Hilary
    Brown, Jennifer
    Stock, Wendy
    Katzen, Harvey
    Lakhanpal, Shailendra
    Jaye, David
    BLOOD, 2007, 110 (11) : 915A - 915A
  • [42] The REVLIRIT CLL5 AGMT Study - a Phase I/II Trial Combining Fludarabine/Rituximab with Escalating Doses of Lenalidomide Followed by Rituximab/Lenalidomide in Untreated Chronic Lymphocytic Leukemia (CLL): Results of a Planned Interim Analysis
    Egle, Alexander
    Steurer, Michael
    Melchardt, Thomas
    Stoll, Marion
    Greil, Richard
    BLOOD, 2009, 114 (22) : 1341 - 1342
  • [43] Fludarabine (F) induces higher response rates in first line therapy of older patients (pts) with advanced chronic lymphocytic leukemia (CLL) than chlorambucil:: Interim analysis of a phase III study of the German CLL study group (GCLLSG).
    Eichhorst, BF
    Busch, R
    Stauch, M
    Kneba, M
    Ritgen, M
    Söling, U
    Burkhard, O
    Bergmann, M
    Wendtner, CM
    Hiddemann, W
    Emmerich, B
    Hallek, M
    BLOOD, 2003, 102 (11) : 109A - 109A
  • [44] Fludarabine plus cyclophosphamide (FC) induces higher remission rates and longer progression free survival (PFS) than fludarabine (F) alone in first line therapy of younger patients (PTS) with chronic lymphocytic leukemia (CLL): Results of a phase III study of the German CLL Study Group (GCLLSG)
    Eichhorst, B
    Busch, R
    Emmerich, B
    Hallek, M
    ANNALS OF ONCOLOGY, 2005, 16 : 89 - 90
  • [45] Navitoclax (ABT-263) Plus Fludarabine/Cyclophosphamide/Rituximab (FCR) or Bendamustine/Rituximab (BR): A Phase 1 Study in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL)
    Kipps, Thomas J.
    Swinnen, Lode J.
    Wierda, William G.
    Jones, Jeffrey Alan
    Coutre, Steven E.
    Smith, Mitchell R.
    Yang, Jainning
    Cui, Yue
    Busman, Todd
    Enschede, Sari
    Humerickhouse, Rod
    BLOOD, 2011, 118 (21) : 1669 - 1669
  • [46] Navitoclax (ABT-263) Plus Fludarabine/Cyclophosphamide/Rituximab (FCR) or Bendamustine/Rituximab (BR): A Phase 1 Study In Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL)
    Kipps, Thomas J.
    Wierda, William G.
    Jones, Jeffrey A.
    Swinnen, Lode J.
    Yang, Jianning
    Cui, Yue
    Busman, Todd
    Krivoshik, Andrew
    Enschede, Sari
    Humerickhouse, Rod
    BLOOD, 2010, 116 (21) : 1019 - 1019
  • [47] NAVITOCLAX (ABT-263) PLUS FLUDARABINE/CYCLOPHOSPHAMIDE/RITUXIMAB (FCR) OR BENDAMUSTINE/RITUXIMAB (BR): A PHASE 1 STUDY IN PATIENTS WITH RELAPSED/REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA (CLL)
    Kipps, T.
    Swinnen, L.
    Wierda, W.
    Jones, J.
    Coutre, S.
    Smith, M.
    Yang, J.
    Cui, Y.
    Chyla, B.
    Busman, T.
    Enschede, S.
    Humerickhouse, R.
    HAEMATOLOGICA, 2012, 97 : 219 - 219
  • [48] Impact of Gender on Outcome after Chemoimmunotherapy with Fludarabine, Cyclophosphamide and Rituximab (FCR) or Bendamustine Plus Rituximab (BR) in Patients with Chronic Lymphocytic Leukemia (CLL): A Meta-Analysis of Three Phase II/III Studies of the German CLL Study Group (GCLLSG)
    Al-Sawaf, Othman
    Robrecht, Sandra
    Bahlo, Jasmin
    Fink, Anna Maria
    Cramer, Paula
    Maurer, Christian
    Bergmann, Manuela A.
    Dreyling, Martin H.
    Lange, Elisabeth
    Kneba, Michael
    Stilgenbauer, Stephan
    Dohner, Hartmut
    Kiehl, Michael G.
    Jager, Ulrich
    Wendtner, Clemens-Martin
    Fischer, Kirsten
    Hallek, Michael
    Eichhorst, Barbara F.
    Hopfinger, Georg
    BLOOD, 2016, 128 (22)
  • [49] Results of a Phase II of Low-Dose Fludarabine and Cyclophosphamide Combined with Standard Dose Rituximab (FCR-LITE) in Elderly, Untreated Patients with Chronic Lymphocytic Leukemia (CLL): The Israeli CLL Study Group Experience
    Tadmor, Tamar
    Herishanu, Yair
    Braester, Andrei
    Bairey, Osnat
    Aviv, Ariel
    Rahimi-Levene, Naomi
    Fineman, Riva
    Levi, Itai
    Yuklea, Mona
    Ruchlemer, Rosa
    Shvideland, Lev
    Polliack, Aaron
    BLOOD, 2018, 132
  • [50] 5-YEAR FOLLOW-UP OF HEAVILY PRETREATED PATIENTS WITH RELAPSED/REFRACTORY CLL IN PHASE 3 STUDY: SIGNIFICANT SURVIVAL BENEFIT WITH OBLIMERSEN PLUS FLUDARABINE/CYCLOPHOSPHAMIDE IN RESPONDING PATIENTS
    O'Brien, M.
    Gribben, J.
    Cousin, T.
    Rai, K.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2009, 94 : 141 - 142
12345